O. Loewenstein

发表

Cancer pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: results from a non-interventional study

T. Nolte, U. Schutter, O. Loewenstein, 2013, Pragmatic and observational research.

Long‐term efficacy and safety of oxycodone‐naloxone prolonged‐release formulation (up to 180/90 mg daily) – results of the open‐label extension phase of a phase III multicenter, multiple‐dose, randomized, controlled study

W. Kremers, M. Hopp, D. Dupoiron, 2017, European journal of pain.

A phase III randomized controlled study on the efficacy and improved bowel function of prolonged‐release (PR) oxycodone‐naloxone (up to 160/80 mg daily) vs oxycodone PR

W. Kremers, M. Hopp, D. Dupoiron, 2017, European Journal of Pain.